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Results: Following ACL section, limb impairment rapidly devel-
oped in all dogs, with PVF and GCA values dropping by week
4. After this acute disability phase, the dogs underwent a slow
remission phase that was still incomplete by week 26. Prediction
of PVF change was best estimated (R2=0.96) from GCA and BML-
SPGR (p<0.0001), particularly during the phase of acute disability,
whereas cartilage defect was more inﬂuential (R2=0.97) during the
remission phase (p=0.0051) (week 8 to week 26). The other joint
structural damages had insigniﬁcant effect on limb impairment and
recovery. Both BML-SPGR and cartilage defect adversely affected
the recovery in PVF, with mutually independent effects.
Similar to ln_PVF, GCA showed an acute drop by week 4, followed
afterwards by a remission phase (p<0.0001), which attained base-
line values by week 26 (p=0,46). The time-course of GCA recovery
was negatively affected by cartilage defect, and was positively af-
fected by joint effusion (p<0.0001 for both variables).
Conclusions: In recent human OA studies, pain and limb im-
pairment were related mostly to BML and joint effusion. Our data
from dogs with experimental OA conﬁrms the role of BML and
joint effusion on limb function. On one hand, BML and carti-
lage defect hinder the recovery of PVF. On the other hand, joint
effusion positively inﬂuences GCA, supporting the existence of
alleviating mechanisms that oppose to abnormal biomechanics.
This study also clariﬁes the role of cartilage and other joint struc-
tural components in OA: cartilage volume and osteophytosis act
as confounding factors with negligible role in limb impairment.
Such structure/function modeling opens promising avenues for as-
sessing outcome of disease-modifying OA drugs at the preclinical
development stage.
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Purpose: The purpose of the study was to evaluate the efﬁcacy
of an ADAMTS-4 and ADAMTS-5 selective inhibitor in a robust
animal model of osteoarthritis (OA).
Methods: All animal studies were performed after IACUC ap-
proval. Male Lewis rats (20 per group) underwent medial meniscal
tear surgery in the right knee joint1. Rats were treated twice daily
by oral gavage with vehicle, selective ADAMTS-4/-5 inhibitor (ASI)
(10, 30, or 100 mg/kg) or a broad-spectrum MMP inhibitor (30
mg/kg), All treatments were initiated 1 day before surgery and
continued for 13 weeks. At the end of the dosing period, rats
were evaluated for normal mobility and plasma was taken for
pharmacokinetic analysis. Weight-bearing on the operated right
leg and contra-lateral left leg was evaluated in the vehicle-treated
and 30 mg/kg ASI-treated groups using an incapacitance meter,
and expressed as grams difference in weight bearing between
right and left leg. Following euthanasia, right knees were collected
for histopathology evaluation including subjective and objective
measures of cartilage degeneration and measures of joint capsule
thickening.
Results: Statistically signiﬁcant decreases in cartilage degenera-
tion scores and width of severe lesions were observed in animals
treated with both 30 and 100 mg/kg BID ASI. No adverse events
were observed in animals treated with any dose of ASI. Broad-
spectrum MMP inhibitor treatment resulted in decreased histologic
evidence of cartilage degradation, but also caused a 40% thick-
ening of the medial joint capsule, 6% lower body weight and a
reluctance to mobilize. The vehicle-treated animals demonstrated
a 27±2 grams decrease in weight bearing on the operated com-
pared to the control limb, while the animals treated with 30 mg/kg
SI had only a 16±2 grams decrease in weight bearing. This 41%
increase in relative weight bearing on the unstable knee was
statistically signiﬁcant.
Conclusions: This study demonstrated that the signiﬁcant reduc-
tion in cartilage degradation following surgical induction of joint
instability observed in gene-deleted ADAMTS-5 and ADAMTS-4/5
mice can also be produced by small molecule inhibition of en-
zyme activity. There were no adverse physiologic effects following
systemic inhibition of ADAMTS-4/5 activity for 13 weeks. The nor-
malization of weight-bearing, after treatment with an efﬁcacious
dose of ASI, indicated that decreasing cartilage degradation as
a result of inhibition of Aggrecanase-mediated aggrecan degra-
dation, positively affected stance and pain. These results support
this strategy of selective ADAMTS-4/5 inhibition as a safe and
effective method of disease modiﬁcation and pain modiﬁcation of
osteoarthritis, and should be evaluated in the clinic.
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Purpose: To evaluate gait pattern recorded on the CatWalk and
pain behaviour in two different rat models of osteoarthritis (OA).
Methods: Twenty-two male Sprague-Dawley rats weighing
200±25g were studied. Two weeks prior to the induction of OA,
animals were trained on the CatWalk runway (Noldus) to traverse
the corridor uninterruptedly. Mechanical allodynia was assessed
by measurement of withdrawal thresholds in response to appli-
cation of von Frey ﬁlaments. During the second week of the
training period, data were collected to obtain baseline values.
One group of rats (n=8) underwent surgical anterior cruciate liga-
ment transection with partial medial menisectomy (ACLT+pMMx)
to mimic a joint instability model and another (n=8) received an
intra-articular injection of monoiodoacetate (MIA) (3mg/30μl) as
an inﬂammatory pain model. After recuperation (2 days MIA, 5
days ACLT+pMMx), the tests were performed for four consecu-
tive weeks. After the behavioural measurement period, rats were
sacriﬁced. Both knee joints were collected for histological assess-
ment as well as spinal cord lumbar enlargements for neuropeptide
analysis by HPLC/ESI/MS/MS. Repeated measure analysis of
variances (linear model) followed by a sequential Bonferonni cor-
rection were performed for gait analysis parameters and von Frey
results.
Results: No signiﬁcant differences were observed in the gait
speed between the three groups at each time point and in com-
parison with the baseline values. Changes in dynamic gait pa-
rameters were observed starting on the ﬁrst day of testing, post
OA-induction, in both models. A tendency towards stabilization
in the surgical model was observed with parameters returning
near to the baseline values (ex. swing phase duration, the swing
speed and the ratio between the stance phase and the com-
plete stepcycle duration). These observations were seen in both
hind limbs, with no statistical differences between the ipsilateral
and the contralateral limbs. Conversely, in the MIA model sig-
niﬁcant changes remained in the injured limb compared to the
contralateral limb in the swing phase duration (p<0.02) and the
swing speed (p0.2). With von Frey ﬁlaments, mechanical sensi-
tisation was observed in the ipsilateral limb of the MIA model
only (p<0.0001). Neuropeptide analysis demonstrated signiﬁcant
increase in CGRP concentrations in both models with 5803±1520
pmol/g and 4651±586pmol/g in the ACLT+pMMx and MIA models
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respectively (controls: 2541±293pmol/g) (p<0.05). Although sub-
stance P levels in the the ACLT+pMMx (160±39 pmol/g) and the
MIA model (226±67pmol/g) were elevated when compared to the
control group (111±49 pmol/g), this difference was not statistically
signiﬁcant. However, dynorphin concentrations were signiﬁcantly
decreased with concentrations of 370±70 and 418±107 in the
ACLT+pMMx and MIA models respectively (controls: 779±111
pmol/g) (p<0.05). Histological evaluation revealed severe carti-
lage loss in the MIA model and comparatively minor changes
in the ACLT+pMMx model, conﬁrming articular lesions in both
models.
Conclusions: Clearer behavioural nociceptive responses related
to gait parameters of the osteoarthritic limb were seen with the MIA
model suggesting that it may be a better model for the evaluation
of therapeutic strategies for joint pain palliation when compared to
the ACLT+pMMx model, with respect to the length of the study.
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Purpose: Protein Kinase C zeta (PKCζ) is an atypical PKC that
is up-regulated in human osteoarthritis (OA) and has a role in
aggrecanase induction and proteoglycan release. This study was
designed to compare the severity of osteoarthritis (OA) in wild-
type (WT) and PKCζ knock out (KO) mice following challenge in a
surgical-instability model.
Methods: All animal studies were performed with IACUC ap-
provals. The PKCζ KO was generated in-house on a 129SvEv
background with deletion of exon 7 resulting in a frameshift stop
and elimination of both PKCζ and PKMζ expression. PKCζ KO and
sibling WT male mice (22 per group) underwent surgical desta-
bilization of the medial meniscus (DMM) when 10 weeks of age,
and were group housed until sacriﬁced 8 weeks later. Following
euthanasia, right knees were collected for histopathologic evalua-
tion of cartilage degeneration. Safranin-O stained parafﬁn sections
were examined at 80μm intervals through the joint to generate
both summed and maximal scores from all 4 quadrants of the
femoro-tibial joint.
Results: The PKCζ KO mice were grossly normal with no fertility
issues. Severe cartilage degeneration was observed in the sibling
WT at 8-weeks following DMM. In contrast, the PKCζ KO had only
mild to moderate cartilage degeneration. The cartilage degener-
ation scores revealed very signiﬁcant decreases in summed and
maximal scores in the PKCζ KO, when compared to sibling WT.
Conclusions: Previous studies have found that PKCζ expression
is transcriptionally up-regulated in human OA cartilage compared
to normal cartilage, is rapidly phosphorylated following IL-1 stimu-
lation, and PKCζ inhibitors can block aggrecanase expression and
proteoglycan release from cartilage explants. This study demon-
strated that deletion of the catalytic domain of PKCζ (present in
both PKCζ and PKMζ) provides signiﬁcant protection in the DMM
model in the mouse. Previous DMM studies (not published) have
shown a lack of protection with a different PKCζ KO, which main-
tained PKMζ expression. These ﬁndings indicate the importance
of the catalytic domain of PKCζ and the potential of inhibitors
selectively directed to this region to provide disease-modiﬁcation
for the treatment of OA.
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Purpose: Animal models are frequently used in medical research.
The use of the Pond-Nuki model is well established in the ﬁeld of
Osteoarthritis (OA). In the past years, the use of 3D kinematics
has gained in popularity because it provides objective means of
assessing the function of joints/limbs. To this date, most in vitro
studies analyzing kinematics of the canine stiﬂe were made in 2D
under low static loads. To the authors’ knowledge, this model is the
ﬁrst quasi-dynamic weight bearing in vitro model of 3D kinematics
of the canine cranial cruciate ligament deﬁcient stiﬂe.
Goal: Our goal was to use a validated experimental device sim-
ulating a quasi-dynamic model of the stance phase at trot of the
canine hind limb under near physiologic conditions in the cranial
cruciate ligament deﬁcient stiﬂe (CCLDS).
Hypotheses: 1) Kinematics generated by the device is represen-
tative of reported in vivo 3D kinematics in dogs with CCLDS;
2) Peak vertical forces generated by the loaded limbs in the device
are comparable to those recorded in the literature for a trotting
dog during the stance phase.
Methods: Six normal paired hind limbs were harvested from 3
adult large breed dogs euthanatized for reasons unrelated to this
study. The dogs were similar in age, size and body weight (range,
29.5-31 kg). The limbs were prepared and mounted on a previ-
ously validated experimental device. Each limb was submitted to
vertical loading (9 kg). The gait was simulated with a computer-
ized sequence using a linear actuator and a rotational motor. The
stance phase of the gait at trot was simulated three times on each
hind limb. Then, with the limbs still mounted in the device, the cra-
nial cruciate ligament (CCL) was completely transected through a
small medial arthrotomy which was closed using a simple contin-
uous pattern. Kinematics of the tibia and femur was measured in
the 2 situations (intact and CCLDS) with an optoelectronic system.
Vertical ground reaction forces were measured with a 2.5 kN ax-
ial/torsion force transducer. Amplitude of motion and peak ground
reaction forces as well as the general shape of kinematics curves
were also compared with in vivo curves described in the literature.
Results: The comparison of the six average curves of motion
collected on the tested stiﬂes to those from in vivo trials re-
veals similar patterns. Data recorded during in vitro simulations
in CCLDS highlighted the following changes between intact and
CCLDS: an increase in ﬂexion (4°), abduction (2°), internal rota-
tion (3°), cranial translation (4mm), medial translation (1,5mm) and
proximal displacement (3mm) of the tibia were recorded. These
changes are comparable to those reported in vivo. However, the
amplitude of changes is slightly greater on in vivo curves. Peak
vertical forces measured in the device (138±2N) were also similar
to in vivo trials reported in the literature.
Conclusions: Results show that the device generates reliable
motion on a loaded limb which is representative of the in vivo
3D kinematics in CCLDS reported in the literature. This model
could be used to evaluate the impact of OA on kinematics in the
Pond-Nuki model. Furthermore, this model could be used ex vivo
to evaluate the effect of different therapeutic modalities of OA.
Finally and of utmost importance, this model could be adapted
and used with the human knee.
